In support, the higher immature B cell count, higher CD4+ central memory T cell count, and lower CD8+ naive T cell count among breast cancer survivors, which were significantly different between groups, were lost when controlling for age, but–importantly (see next paragraph)—were not lost when controlling for CMV serostatus. This evidence concerns the gene CD4 and breast carcinoma.